The ROE as of September 2024 (TTM) for MiNK Therapeutics, Inc. (INKT) is 99.78%

According to MiNK Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 99.78%. This represents a change of 287.53% compared to the average of 25.75% of the last 4 quarters.

MiNK Therapeutics, Inc. (INKT) Historical ROE (quarterly & annually)

How has INKT ROE performed in the past?

The mean historical ROE of MiNK Therapeutics, Inc. over the last ten years is 1.26%. The current 99.78% ROE has changed -92.08% with respect to the historical average. Over the past ten years (40 quarters), INKT's ROE was at its highest in in the December 2022 quarter at 1.87%. The ROE was at its lowest in in the March 2023 quarter at -3631.48%.

MiNK Therapeutics, Inc. (INKT) ROE by Quarter and Year

Discovering the peaks and valleys of MiNK Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

MiNK Therapeutics, Inc. (INKT) Average ROE

How has INKT ROE performed in the past?

The current ROE of MiNK Therapeutics, Inc. (INKT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

MiNK Therapeutics, Inc. (INKT) ROE vs. Peers

How is INKT’s ROE compared to its peers?

MiNK Therapeutics, Inc.’s ROE is greater than Affimed N.V. (-155.57%), greater than ImmunoGen, Inc. (-21.97%), greater than Adaptimmune Therapeutics plc (-117.47%), greater than Sangamo Therapeutics, Inc. (-334.92%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Inozyme Pharma, Inc. (-68.93%), greater than VectivBio Holding AG (-56.92%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than HOOKIPA Pharma Inc. (-51.77%), less than Kineta, Inc. (934.78%), greater than Candel Therapeutics, Inc. (-629.29%), greater than Forte Biosciences, Inc. (-117.85%), greater than AlloVir, Inc. (-96.48%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Design Therapeutics, Inc. (-18.48%), greater than Werewolf Therapeutics, Inc. (-48.25%), greater than Ikena Oncology, Inc. (-42.81%), greater than Stoke Therapeutics, Inc. (-57.89%),

Build a custom stock screener for MiNK Therapeutics, Inc. (INKT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MiNK Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

MiNK Therapeutics, Inc. (INKT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like MiNK Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.